RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria

        Duygu Ağagündüz,Fatma Nur Keskin,Teslime Özge Şahin,Raffaele Capasso 대한소아청소년과학회 2023 Clinical and Experimental Pediatrics (CEP) Vol.66 No.8

        Phenylketonuria (PKU), an autosomal recessive inherited metabolic disorder, is caused by a mutation in the phenylalaninehydroxylase (PAH) gene on the 12th chromosome. DefectivePAH activity ultimately leads to increased phenylalanine (Phe)blood concentrations (hyperphenylalaninemia) that harm thebrain. The primary purpose of PKU treatment is to maintainthe blood Phe level to prevent certain undesired effects. Hence, lifelong medical nutrition therapy is recommendedfor these patients. The usefulness of natural protein sourcesmay be limited, as they are based on individual Phe tolerance,and a patient’s daily protein requirements are supported byPhe-free amino acid mixtures. A few PKU treatment centersrecently started using supplemental casein glycomacropeptide,pegvaliase, or large neutral amino acids, and some patients aretreated by responding to tetrahydrobiopterin, which works asa pharmaceutical chaperone (prescribed as sapropterin dihydrochloride). This review discusses the efficacy and safetyconsiderations of basic medical nutrition approaches and newgeneration protein substitutes that are used to treat PKU.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼